Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma

Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma

Jan 22, 2021
|
staff reporter

NEW YORK – Kuur Therapeutics reported interim data on Thursday on its autologous GD2-targeting CAR NK-cell therapy, KUR-501, from a Phase I trial involving relapsed or refractory neuroblastoma patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

  2. Epizyme Exploring Tazverik Combinations in Basket Trials

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.